ENTRY       D08985                      Drug
NAME        Reslizumab (USAN);
            Cinqaero (TN);
            Cinqair (TN)
PRODUCT     CINQAIR (Teva Respiratory)
CLASS       Immunological agent
             DG02019  Interleukin inhibitor
REMARK      ATC code: R03DX08
            Product: D08985<US>
EFFICACY    Antiasthmatic, Anti-IL-5 antibody
  DISEASE   Asthma, eosinophilic phenotype [DS:H00079]
  TYPE      Monoclonal antibody
TARGET      IL5 [HSA:3567] [KO:K05428]
  PATHWAY   hsa04060(3567)  Cytokine-cytokine receptor interaction
            hsa04630(3567)  JAK-STAT signaling pathway
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             R RESPIRATORY SYSTEM
              R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
               R03D OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
                R03DX Other systemic drugs for obstructive airway diseases
                 R03DX08 Reslizumab
                  D08985  Reslizumab (USAN) &lt;US&gt;
            USP drug classification [BR:br08302]
             Respiratory Tract/Pulmonary Agents
              Respiratory Tract Agents, Other
               Immunomodulators
                Reslizumab
                 D08985  Reslizumab (USAN)
            Drug groups [BR:br08330]
             Immunological agent
              DG02019  Interleukin inhibitor
               D08985  Reslizumab
            Drug classes [BR:br08332]
             Immunological agent
              DG02019  Interleukin inhibitor
               D08985  Reslizumab
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokines
               Interleukins
                IL5
                 D08985  Reslizumab (USAN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D08985
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D08985
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D08985
DBLINKS     CAS: 241473-69-8
            PubChem: 96025668
///
